Pulmonary vascular disease

Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study
H.A. Ghofrani, M.M. Hoeper, M. Halank, F.J. Meyer, G. Staehler, J. Behr, R. Ewert, G. Weimann, F. Grimminger

European Respiratory Journal Oct 2010, 36 (4) 792-799; DOI: 10.1183/09031936.00182909
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil
K.T.B. Mouchaers, I. Schalij, M.A. de Boer, P.E. Postmus, V.W.M. van Hinsbergh, G.P. van Nieuw Amerongen, A. Vonk Noordegraaf, W.J. van der Laarse

European Respiratory Journal Oct 2010, 36 (4) 800-807; DOI: 10.1183/09031936.00130209
Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension
B.K. Dahal, D. Kosanovic, P.K. Pamarthi, A. Sydykov, Y-J. Lai, R. Kast, H. Schirok, J-P. Stasch, H.A. Ghofrani, N. Weissmann, F. Grimminger, W. Seeger, R.T. Schermuly

European Respiratory Journal Oct 2010, 36 (4) 808-818; DOI: 10.1183/09031936.00140309
Tetrahydrobiopterin and the regulation of hypoxic pulmonary vasoconstriction
B.N. Francis, M.R. Wilkins, L. Zhao

European Respiratory Journal Aug 2010, 36 (2) 323-330; DOI: 10.1183/09031936.00188809
Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan
L. Kiakouama, V. Cottin, B. Etienne-Mastroïanni, C. Khouatra, M. Humbert, J.F. Cordier

European Respiratory Journal Jul 2010, 36 (1) 202-204; DOI: 10.1183/09031936.00004810

Main menu